New Non Hormonal Therapies and Needle Free Epinephrine Advance Patient Care in 2025

New Non Hormonal Therapies and Needle Free Epinephrine Advance Patient Care in 2025
Why this is good news

    New treatments for menopause symptoms and severe allergies offer relief without hormones or needles.

  • Two new non-hormonal pills.Before, women who couldn't use hormone therapy had very few options for severe hot flashes. Now, Lynkuet and Veozah provide effective, targeted alternatives by calming the brain's temperature control neurons.
  • Lynkuet joins existing Veozah.Having only one non-hormonal drug limited patient access and choice. A second approved option, Lynkuet, creates competition and increases the likelihood that more women will find a treatment that works for them.
  • Needle-free epinephrine delivery.People with severe allergies previously had to carry and use an injector, which can be intimidating. A needle-free method could make emergency treatment faster and less stressful during a life-threatening reaction.
  • Options for over 80% of women.The vast majority of menopausal women experience disruptive hot flashes with limited solutions. These specific breakthroughs directly address this massive, underserved patient population with new science.

Scientific progress in 2025 delivered significant new treatment options for common yet debilitating health challenges, from menopause symptoms to severe allergic reactions, offering relief to patients with limited alternatives.

For the more than 80 percent of women who experience disruptive hot flashes during menopause, two new non-hormonal pills now provide options where few existed. Lynkuet (elinzanetant), approved this year, joins Veozah (fezolinetant) in targeting temperature-regulating neurons in the brain. This approach offers a crucial alternative for women who cannot use traditional hormone therapy due to histories of certain cancers or other health conditions.

In pediatric allergy care, a major update arrived with the approval of Neffy, the first needle-free epinephrine nasal spray for children. Designed for kids ages four and older weighing 33 to 65 pounds, the spray uses a novel technology to rapidly absorb the drug into the bloodstream. With food allergies affecting one in 13 children, this easier-to-administer format could help overcome the hesitation associated with auto-injectors and ensure faster intervention during life-threatening anaphylactic reactions.

Beyond these approvals, regenerative medicine saw foundational advances. Scientists studying salamanders identified key molecules involved in limb regrowth, providing a blueprint that could one day guide human therapies. Separately, researchers successfully implanted lab-grown heart muscle patches in monkeys and, for the first time, used stem cells to create functioning ureter tissue, marking early steps toward repairing damaged organs.

Looking ahead, these breakthroughs signal a shift toward more accessible and personalized medicine. The new menopause treatments are already reaching patients, while the needle-free epinephrine spray is expected to become a standard part of allergy emergency kits. The underlying discoveries in regeneration and genetics continue to pave the way for future therapies that could one day rebuild tissues and cure rare diseases, reflecting a year of tangible progress for human health.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.

← Back to all stories
Medical Disclaimer: Content on Curative News is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.